Author Archives: Steph

August 11, 2020
In The News

[TechCrunch] With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions.

Read Article
August 11, 2020
In The News

[Wall Street Journal] Atomwise Inc., which uses artificial intelligence to help academic and commercial scientists discover new medicines, has raised $123 million to expand and build its own pipeline of experimental drugs.

Read Article
January 13, 2020
Press Release

Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research CLEVELAND & SAN FRANCISCO–(BUSINESS WIRE)–BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies. The organizations will form co-owned, joint […]

Read Article
January 7, 2020
Press Release

Companies to continue crop protection development programs January 07, 2020 08:30 AM Eastern Standard Time MONHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the companies will continue the development of two crop protection programs. Farmers across the world are facing an increase in weed, insect and […]

Read Article
November 14, 2019
In The News

Molecule prospector Atomwise co-founded a drug research company alongside Velocity Pharmaceutical Development designed to shepherd its artificial intelligence-derived candidates through preclinical testing and into potential takeout deals with pharma industry partners. Dubbed X-37, the new firm will maintain a flexible LLC structure that will house each development program within its own virtual subcompany. This will […]

Read Article
June 3, 2019
Press Release

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]

Read Article